Bulletin
Investor Alert

London Markets Open in:

Denali Therapeutics Inc.

NAS: DNLI

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 26, 2022, 6:08 p.m.

/zigman2/quotes/200043077/composite

$

34.00

Change

+0.75 +2.26%

Volume

Volume 7,402

Quotes are delayed by 20 min

/zigman2/quotes/200043077/composite

Previous close

$ 33.73

$ 33.25

Change

-0.48 -1.42%

Day low

Day high

$33.03

$36.14

Open

52 week low

52 week high

$30.25

$79.70

Open

David Paul Schenkein

Dr. David P. Schenkein, MD, is a General Partner at GV Management Co. LLC, an Independent Director at Denali Therapeutics, Inc. and an Executive Chairman at Agios Pharmaceuticals, Inc. He is on the Board of Directors at Denali Therapeutics, Inc., Biotechnology Innovation Organization, Prime Medicine, Inc., Treeline Biosciences, Inc. and Leyden Laboratories B.V. Dr. Schenkein was previously employed as an Independent Director by bluebird bio, Inc., an Independent Director by Blueprint Medicines Corp., an Independent Director by Foundation Medicine, Inc., a Senior Vice President-Oncology Development by Genentech, Inc., a Senior Vice President-Clinical Research by Takeda Oncology Co., a Venture Partner by ARCH Venture Partners LLC, and an Associate Professor by Tufts Medical Center, Inc. He received his undergraduate degree from Wesleyan University and a doctorate degree from SUNY Upstate Medical University.

Transactions

Date Shares Transaction Value
06/02/2021 2,074   Award at $0 per share. 0
06/01/2021 3,253   Derivative/Non-derivative trans. at $0 per share. 0
12/21/2020 5,000   Disposition at $90.01 per share. 450,050
12/21/2020 25,000   Disposition at $90.06 per share. 2,251,500
11/12/2020 30,000   Disposition at $70.05 per share. 2,101,500
11/10/2020 10,000   Disposition at $60.03 per share. 600,300
11/04/2020 10,000   Disposition at $50.18 per share. 501,800
12/12/2017 19,774   Derivative/Non-derivative trans. at $0 per share. 0
12/12/2017 105,225   Derivative/Non-derivative trans. at $0 per share. 0
12/12/2017 19,774   Derivative/Non-derivative trans. at $0 per share. 0
12/12/2017 105,225   Derivative/Non-derivative trans. at $0 per share. 0

Officers and Executives

Dr. Ryan J. Watts
President, Chief Executive Officer & Director
Dr. Alexander O. Schuth
Chief Operating Officer & Secretary
Mr. Steve E. Krognes
Treasurer, Chief Financial & Accounting Officer
Dr. Joe Lewcock
Chief Scientific Officer
Dr. Carole Ho
Chief Medical Officer & Head-Development
Dr. Dana Andersen
CTO & Chief Manufacturing Officer
Ms. Katie Peng
Chief Commercial Officer
Dr. Laura G. Hansen
Vice President-Investor Relations
Ms. Cindy Dunkle
Chief People Officer
Dr. Chris Walsh
Associate General Counsel
Ms. Erica Kratz
Vice President-Regulatory
Dr. Vicki L. Sato
Non-Executive Chairman
Ms. Nancy A. Thornberry
Independent Director
Dr. Marc Tessier-Lavigne
Independent Director
Dr. Douglas G. Cole
Independent Director
Mr. Jay T. Flatley
Independent Director
Mr. Robert Taylor Nelsen
Independent Director
Dr. David Paul Schenkein
Independent Director
Mr. Peter S. Klein
Independent Director
Ms. Jennifer E. Cook
Independent Director
Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.20%
  • /zigman2/quotes/201948298/composite BABA-5.69%
  • /zigman2/quotes/202092269/composite ENSC+36.10%
  • /zigman2/quotes/200164174/composite SNOA+74.50%
  • /zigman2/quotes/207683784/composite TIGR-10.38%
X
Powered by StockTwits
Link to MarketWatch's Slice.